Copyright
©The Author(s) 2021.
World J Gastroenterol. Dec 21, 2021; 27(47): 8081-8102
Published online Dec 21, 2021. doi: 10.3748/wjg.v27.i47.8081
Published online Dec 21, 2021. doi: 10.3748/wjg.v27.i47.8081
Bulevirtide | Entry inhibitor | Germany | Approved in Europe |
Lonafarnib | Prenylation inhibitor | United States | Phase III |
REP 2139 | HBsAg inhibitor | Canada | Phase II |
Ezetimibe | NTCP inhibitor | Pakistan | Phase II |
- Citation: González Grande R, Santaella Leiva I, López Ortega S, Jiménez Pérez M. Present and future management of viral hepatitis. World J Gastroenterol 2021; 27(47): 8081-8102
- URL: https://www.wjgnet.com/1007-9327/full/v27/i47/8081.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i47.8081